Senti Biosciences, Inc. announced plans to streamline its business operations, including reducing its workforce by approximately 37%, to enable increased focus on SENTI-202, a first-in-class Logic Gated investigational cell therapy for the treatment of acute myeloid leukemia.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3 USD | -4.15% | -11.79% | -54.55% |
May. 17 | Senti Biosciences, Inc. Announces Executive Changes | CI |
May. 09 | Senti Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
1st Jan change | Capi. | |
---|---|---|
-54.55% | 13.73M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- SNTI Stock
- News Senti Biosciences, Inc.
- Spark Therapeutics, Inc. Announces Workforce Reduction